Screener
Ironwood Pharmaceuticals IRWD EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Ironwood Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
FAQ
- What is Ironwood Pharmaceuticals's EV / EBITDA?
- Ironwood Pharmaceuticals (IRWD) reported EV / EBITDA of 2.7× in Q2 2026.
- How has Ironwood Pharmaceuticals's EV / EBITDA changed year-over-year?
- Ironwood Pharmaceuticals's EV / EBITDA decreased by 16.7% year-over-year, from 3.2× to 2.7×.
- What is the long-term trend for Ironwood Pharmaceuticals's EV / EBITDA?
- Over 4 years (2020 to 2025), Ironwood Pharmaceuticals's EV / EBITDA has grown at a -14.6% compound annual growth rate (CAGR), from 10.2× to 5.4×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Ironwood Pharmaceuticals's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude